Priyanka Belawat

Dr. Priyanka Belawat is an Investment Advisor for HBM Healthcare Investments. Dr. Belawat has 10 years of experience in venture and private equity investing in the healthcare space. She has been instrumental in many portfolio investments of HBM funds in areas of biotech, pharma diagnostics, and services. Presently, she represents HBM funds on the board of Neurelis Inc. and is a board observer to ARMO Biosciences (USA, Immuno-oncology), TrueNorth Therapeutics (the USA, Rare diseases), SAI Lifesciences (India, Contract research and manufacturing), and 1MG (India, Online pharma portal). She was closely involved with HBM’s investment in Advanced Accelerator Applications (NASDAQ: AAAP), a French company in the radio-therapeutics and radio-diagnostics space, which went public on US NASDAQ in 2014. She also has extensive knowledge of the Indian pharma sector and has been involved in various public equity, fund, and direct private investments in India.

Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and completed post-doctorate work at HKUST.